Atria reported Q2 adjusted EBIT of EUR 17.6m, 7% above LSEG Data & Analytics consensus.
Vitrolife faces a tough 2025, and we expect this to continue during H2 2025, at best, at a fading ra...
Redeye comments on OncoZenge’s recent amendment to its licensing agreement with Molteni Farmaceutici...
Redeye shares its initial thoughts on CTEK’s Q2 report, which we think came in slightly softer than ...
Q2'25 details Prevas reports Q2'25 sales of SEK 409m (-4% vs.
Redeye sees a soft Q2 report from Stille, marked by headwinds in the surgical instruments business, ...
Redeye states that the Q2 report came in broadly in line with our expectations, with a high YoY net ...
Redeye comments on Evolutions Q2-results, which were in line with our expectations, albeit with slig...
Redeye provides its first take on Camurus’ Q2 report 2025, published this morning.
Net sales and EBIT were slightly below market consensus (LSEG) in Q2.
Redeye believes Enea’s share price has further to run following the positive market reaction to its ...
Redeye updates its estimates and valuation for Serstech following the Q2 2025 report.
Selective recruitment in H2'25 Q2 missed on sales and adj.
Servicebolaget Coor rapporterade ett starkt kvartal som överträffade vår prognos.
Redeye comments on the conversion of warrants and Cantargia's deal yesterday.
